SPRIND to finance spin-off Plectonic
The Federal Agency for Disruptive Innovation SPRIND will provide funding for the work of Plectonic Biotech in the coming years. The TUM spin-off has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of immunotherapies that target tumors specifically and have fewer side effects.
Immunotherapies are regarded as one of the most promising approaches to cancer treatment in the future. These treatments mobilize the body’s own immune system to attack cancer cells. An important goal is to achieve high efficacy in the immune response to cancer cells while minimizing side effects. To address this challenge, the Plectonic team, led by founders Dr. Klaus Wagenbauer, Dr. Jonas Funke, Dr. ...
